Business
DRI Healthcare Comments on FDA Approval and our Increased Investment in KalVista Pharmaceuticals' Ekterly® (sebetralstat)
DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today announced KalVista Pharmaceuticals ("KalVista") has disclosed it has received approval from the U.S. Food and Drug Administration ("FDA") for Ekterly (sebetralstat). Ekterly is approved for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. HAE is a rare genetic disorder characterized by recurring episodes of severe swelling in various parts of the body, in
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":"– Ekterly is the first and only oral on-demand therapy for treating attacks associated with hereditary angioedema –","length":115,"tagName":"p","attribs":{}},{"type":"text","content":"– DRI Healthcare is entitled to a tiered royalty on worldwide net sales of Ekterly –","length":84,"tagName":"p","attribs":{}},{"type":"text","content":"– KalVista has elected to receive additional funding increasing our total investment to $127 million –","length":102,"tagName":"p","attribs":{}},{"type":"text","content":"TORONTO, July 8, 2025 /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today announced KalVista Pharmaceuticals ("KalVista") has disclosed it has received approval from the U.S. Food and Drug Administration ("FDA") for Ekterly (sebetralstat). Ekterly is approved for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. HAE is a rare genetic disorder characterized by recurring episodes of severe swelling in various parts of the body, including the face, extremities, gastrointestinal tract, and airways.","length":652,"tagName":"p"},{"type":"image","alt":"DRI Healthcare Trust (TSX: DHT.UN, DHT.U) (CNW Group/DRI Healthcare Trust)","displaySize":"","headline":null,"caption":"DRI Healthcare Trust (TSX: DHT.UN, DHT.U) (CNW Group/DRI Healthcare Trust)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":50,"url":"https://media.zenfs.com/en/cnwgroup.com/812ffbca63fa8f40eb7e6773b0a4c3db"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bTReMYXNAGW9KTfiqJlp9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTg4O2NmPXdlYnA-/https://media.zenfs.com/en/cnwgroup.com/812ffbca63fa8f40eb7e6773b0a4c3db","width":400,"height":50}},"href":"https://mma.prnewswire.com/media/2726294/DRI_Healthcare_Trust_DRI_Healthcare_Comments_on_FDA_Approval_and.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We are very pleased that the FDA has approved Ekterly as the first and only oral on-demand therapy for treating HAE attacks," said Ali Hedayat, Chief Executive Officer of DRI Healthcare. "The addition of the long-dated Ekterly cash flows demonstrates the value that a pre-approval transaction can bring to our portfolio."","length":342,"tagName":"p"},{"type":"te...